Efficacy, immunogenicity, and safety of a plant-derived, quadrivalent, virus-like particle influenza vaccine in adults (18–64 years) and older adults (≥65 years): two multicentre, randomised phase 3 trials-Reference-Cited by-同舟云学术

Efficacy, immunogenicity, and safety of a plant-derived, quadrivalent, virus-like particle influenza vaccine in adults (18–64 years) and older adults (≥65 years): two multicentre, randomised phase 3 trials

Published:2020-11 Issue:10261 Volume:396 Page:1491-1503
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Ward Brian J,Makarkov Alexander,Séguin Annie,Pillet Stéphane,Trépanier Sonia,Dhaliwall Jiwanjeet,Libman Michael D,Vesikari Timo,Landry Nathalie

Publisher

Elsevier BV

Subject

General Medicine

Reference43 articles.

1. The burden of influenza: a complex problem;Gordon;Curr Epidemiol Rep,2018

2. Vaccine effectiveness against lineage-matched and -mismatched influenza B viruses across 8 seasons in Canada, 2010–2011 to 2017–2018;Skowronski;Clin Infect Dis,2019

3. Seasonal and pandemic influenza: global fatigue versus global preparedness;Gilbert;Lancet Respir Med,2018

4. A tale of two mutations: beginning to understand the problems with egg-based influenza vaccines?;Subbarao;Cell Host Microbe,2019

5. Egg-independent influenza vaccines and vaccine candidates;Manini;Vaccines,2017

Cited by 143 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring recent progress of molecular farming for therapeutic and recombinant molecules in plant systems;Heliyon;2024-09

2. Could molecular farming be a game changing paradigm in the production of immune checkpoint inhibitors for cancer immunotherapy?;Vacunas;2024-08

3. Virus-like Particles as Vaccines for Allergen-Specific Therapy: An Overview of Current Developments;International Journal of Molecular Sciences;2024-07-06

4. Immunogenicity and safety evaluation of a newly manufactured recombinant Baculovirus-Expressed quadrivalent influenza vaccine in adults 18 years old and Above: An Open-Label, phase III extension study;International Immunopharmacology;2024-07

5. Development of a Fully Protective Pandemic Avian Influenza Subunit Vaccine in Insect Pupae;Viruses;2024-05-23